Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

December 02, 2024 07:00 ET | Source: Autolus Therapeutics plc

Autolus Therapeutics Announces Publication of Data from the FELIX study of obe-cel in r/r Adult B-ALL Patients in The New England Journal of Medicine

High overall response rate: 76.6% of patients in the pivotal cohort achieved CR/Cri following treatment with obe-cel with a median follow-up of 20.3 monthsLow incidence of immune-related toxicity:...
November 03, 2023 10:46 ET | Source: Travere Therapeutics, Inc.

Travere Therapeutics Announces Late-Breaking Data from Phase 3 Studies of Sparsentan in IgAN and FSGS Published in The Lancet and The NEJM Respectively and Presented at the American Society of Nephrology (ASN) Kidney Week 2023

“The totality of data from the PROTECT study demonstrates FILSPARI is effective, safe and has an important place in the IgAN treatment landscape ..."
June 08, 2023 00:20 ET | Source: Burning Rock Biotech Limited

Burning Rock's precision oncology diagnostics product supports advancement in late-stage breast cancer treatment, with results published in the New England Journal of Medicine

GUANGZHOU, China, June 08, 2023 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ: BNR and LSE: BNR, the “Company” or “Burning Rock”) is pleased to announce that our flagship comprehensive...
February 23, 2023 08:05 ET | Source: uniQure Inc.

uniQure Announces HOPE-B Clinical Trial Data Published in the New England Journal of Medicine, Demonstrating Durability and Other Benefits of HEMGENIX® (etranacogene dezaparvovec-drlb)

~ Data follow the historic approval of the first gene therapy for hemophilia B, which has been shown in clinical trials to reduce the rate of annual bleeds, reduce or eliminate the need for...
December 22, 2021 17:48 ET | Source: Intermountain Healthcare

Intermountain Healthcare Researchers Play Key Role in New Study Finding Antiviral Drug is Effective in Preventing Severe Illness in COVID Patients When Given Early

Salt Lake City, Dec. 22, 2021 (GLOBE NEWSWIRE) -- Researchers from Intermountain Healthcare played a key role in a new international study that has found that an antiviral drug designed to inhibit...
February 17, 2021 17:13 ET | Source: BioNTech SE

Im The New England Journal of Medicine veröffentlichte in-vitro-Daten zeigen, dass Seren von mit dem Pfizer-BioNTech COVID-19-Impfstoff geimpften Personen SARS-CoV-2 mit der Südafrika-Spike-Mutation neutralisieren

New York, USA und Mainz, DEUTSCHLAND, 17. Februar 2021 (GLOBE NEWSWIRE) — Pfizer Inc. (NYSE: PFE) und BioNTech SE (Nasdaq: BNTX) gaben heute Ergebnisse einer in-vitro-Studie bekannt, die zusätzliche...
February 17, 2021 17:13 ET | Source: BioNTech SE

In Vitro Study Published in The New England Journal of Medicine Demonstrates Sera from Individuals Immunized with the Pfizer-BioNTech COVID-19 Vaccine Neutralize SARS-CoV-2 with South African Variant Spike Mutations

New York, NY and Mainz, Germany, February 17, 2021 (GLOBE NEWSWIRE) — Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced results from an in vitro study that provides additional...
July 08, 2020 17:01 ET | Source: Biogen Inc.

The New England Journal of Medicine Publishes Final Results from Phase 1/2 Study of Tofersen for a Genetic Form of ALS

Tofersen is an investigational molecule for superoxide dismutase 1 (SOD1) amyotrophic lateral sclerosis (ALS), the second most common genetic form of ALS, a progressive neurodegenerative diseaseFinal...
July 24, 2019 18:53 ET | Source: FibroGen, Inc

The New England Journal of Medicine (NEJM) Publishes Roxadustat China Phase 3 Results for the Treatment of Anemia in Chronic Kidney Disease Patients Receiving Dialysis

-- One of Two Concurrent Publications of Roxadustat China Phase 3 Results in The New England Journal of Medicine -- SAN FRANCISCO, July 24, 2019 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN)...
January 30, 2019 15:00 ET | Source: ARTIS Ventures

Largest Study of Its Kind Uses AI to Identify Unmet Needs of Patients with Severe Chronic Conditions; Emotional Support Takes Top Spot

San Francisco, Jan. 30, 2019 (GLOBE NEWSWIRE) -- Today, NEJM Catalyst published new research co-authored by healthcare executives from UCB, ARTIS Ventures and Quid, that analyzed more than 500,000...

Next Page keyboard_arrow_right